Chromium picolinate supplementation for overweight or obese adults

Tian, Hui; X, Guo; Wang, Xiyu; He, Zhaohong; Sun, Renhua; Ge, Shaohua; Zhang, Zongjiu

doi:10.1002/14651858.cd010063.pub2

Cited by 42 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Administration of this trace element has been used as a strategy to intervene in chronic, low-grade inflammation related to obesity, insulin resistance, and type 2 diabetes mellitus [18]; chromium acts directly on insulin receptor mechanisms that augment cellular glucose uptake [17,54]. However, the available evidence is not sufficient to ascertain the beneficial effects of chromium in patients in different BMI ranges, with and without type 2 diabetes [55,56]. In this sense, although the studies included in our qualitative analysis compared Guler [43] 2014 **** ** *** Celik [45] 2013 **** ** *** Chakraborty [46] 2013 **** ** *** Kurdoglu [47] 2012 **** ** *** PCOS patients (who have a worse metabolic profile) with controls, no differences were observed between the groups in serum chromium levels [42,46].…”

Section: Discussionmentioning

confidence: 99%

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Spritzer

Lecke

Fabris

et al. 2016

Biol Trace Elem Res

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a prevalent condition in women of reproductive age. PCOS is characterized by androgen excess and chronic anovulation and associated with low-grade inflammation and metabolic comorbidities. Some trace elements have been linked to pathophysiological mechanisms of oxidative stress and inflammation in different disorders. Therefore, we conducted a systematic review and meta-analysis of the available evidence regarding trace element concentrations in PCOS. We reviewed MEDLINE and EMBASE in search of case-control, cross-sectional, and cohort studies published until September 2015. Of 183 studies identified, six were selected for systematic review. All used the Rotterdam criteria for the diagnosis of PCOS. Two studies evaluating chromium and one assessing cobalt levels did not observe differences between PCOS and controls. Another study recorded similar nickel and vanadium levels between the groups, but lower selenium concentrations in women with PCOS compared to controls. Four studies were included in the random effects model meta-analysis, for a total of 264 PCOS and 151 control women. Copper levels were found to be higher in women with PCOS than in controls [mean difference 0.12 ppm (95 % CI 0.07; 0.17 ppm); I 2 = 0 %]. Manganese [mean difference 0.04 ppm (95 % CI −0.05; 0.13 ppm); I 2 = 94.4 %] and zinc concentrations [mean difference 0.02 ppm (95 % CI −0.12; 0.16 ppm); I 2 = 92.4 %] were similar between the groups. The present results suggest a relationship between increased copper concentration and PCOS. This systematic review and meta-analysis is registered in PROSPERO under number CRD42016034036.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Spritzer

Lecke

Fabris

et al. 2016

Biol Trace Elem Res

View full text Add to dashboard Cite

show abstract

“…In particular, a previous meta‐analysis of Onakpoya et al, included 18 trials with 974 subjects . The study of Tian et al was performed in trials in which the picolinate form of chromium supplement was administered. However, it was more comprehensive compared with the one of Onakpoya.…”

Section: Discussionmentioning

confidence: 99%

A meta‐analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity

et al. 2019

View full text Add to dashboard Cite

Summary The role of chromium as a weight loss agent remains questionable, and although previous meta‐analyses findings have reported small reductions in body weight in individuals with overweight/obesity following chromium supplementation, there have been significant limitations with these findings. The objective of this meta‐analysis was to evaluate the current evidence for the efficacy of oral chromium supplementation in individuals with overweight/obesity from randomized controlled trials. Studies were identified by a search of electronic databases from inception to November 2018 and combined and stratified analyses were used. Twenty‐one trials from 19 studies were identified which met all inclusion criteria which were suitable for statistical pooling, and data from 1316 participants were included. Pooled analysis showed significant reductions in anthropometric indices associated with body composition; for weight loss (weighted mean difference [WMD]: −0.75 kg, 95% confidence interval [CI], −1.04, −0.45, P < 0.001), body mass index (WMD: −0.40, 95% CI, −0.66, −0.13, P = 0.003 and body fat percentage (WMD: −0.68%, 95% CI, −1.32, −0.03, P = 0.04) in individuals with overweight/obesity. No changes were detected in controls. Subgroup analysis showed significant improvements in weight loss and body fat percentage, particularly for study durations ≤12 weeks and doses ≤400 μg/d. Chromium supplementation was associated with some improvements in body composition in subjects with obesity/overweight. The effect size was medium and the clinical relevance of chromium as a weight loss aid remains uncertain. Further investigation from larger and well‐designed randomized controlled studies, especially in patients with diabetes, is warranted.

show abstract

“…While previous meta‐analyses failed to show a beneficial effect of chromium supplementation, a more recent meta‐analysis suggested favorable effects of chromium on blood sugar level in diabetic patients . It may be worth noting that some of the aforementioned analyses used poorly absorbed forms of chromium (chromium chloride, chromium yeast) or niacin‐bound chromium (niacin is known to cause IR) …”

Section: Discussionmentioning

confidence: 99%

Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial

Ashoush

Abou-Gamrah

Bayoumy

et al. 2015

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: To investigate the effect of chromium picolinate (CrP) on insulin resistance (IR) in polycystic ovary syndrome (PCOS). Methods: This double blinded randomized controlled trial was conducted in the Gynecology outpatient clinics at Ain Shams University Women's Hospital. Using closed and randomly mixed envelopes, 100 women were selected out of 400 PCOS patients. Eighty-five patients finished the study and were analyzed, 44 in group I and 41 in group II. They were randomly allocated to 6 months of either 1000 μg CrP (50 patients), or placebo capsules (50 patients). Patients were seen monthly to encourage similar diet control and physical exercise plans. The primary outcome was fasting glucose insulin ratio (FGIR), secondary outcomes included ovulation, regularity of the cycle, body mass index (BMI), fasting blood sugar (FBS), fasting serum insulin (FSI), and serum testosterone level. Results: There were no significant differences between women of both groups regarding pretreatment levels of FBS, FSI, FGIR, and serum testosterone. Use of CrP for 6 months was associated with significant reduction of BMI (P < 0.001) and FSI (P = 0.007), and significant rise in FGIR (P = 0.045). CrP significantly increased the chances of ovulation (P = 0.011) and regular menstruation (P = 0.002) by almost twofold after the fifth month of treatment. Conclusion: Chromium picolinate is useful in PCOS to reduce IR and stimulate ovulation.

show abstract

Chromium picolinate supplementation for overweight or obese adults

Cited by 42 publications

References 28 publications

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis

A meta‐analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity

Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: Randomized controlled trial

Contact Info

Product

Resources

About